Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients | Zendy

Solomón Mequanente Abay | Zendy; Mulugeta Tilahun | Zendy; Nigus Fikrie | Zendy; Abiy Habtewold | Zendy

Open Access

Plasmodium falciparum and Schistosoma mansoni coinfection and the side benefit of artemether-lumefantrine in malaria patients

Author(s) -

Solomón Mequanente Abay,

Mulugeta Tilahun,

Nigus Fikrie,

Abiy Habtewold

Publication year - 2013

Publication title -

the journal of infection in developing countries

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.322

H-Index - 49

eISSN - 2036-6590

pISSN - 1972-2680

DOI - 10.3855/jidc.2658

Subject(s) - artemether/lumefantrine , coinfection , artemether , malaria , plasmodium falciparum , schistosoma mansoni , virology , medicine , lumefantrine , immunology , biology , schistosomiasis , human immunodeficiency virus (hiv) , helminths , artemisinin

The distribution of both malaria and schistosomiasis exhibits a large geographical overlap in tropical environments, particularly in sub-Saharan Africa. This part of the world currently harbours more than 85% of the estimated global burden of these diseases. Studies showed that artemisinin derivatives used for the treatment of malaria also have an antischistosomal effect. This study aimed to investigate the extent of malaria-schistosomiasis co-infection and the antischistosomal effect of artemether-lumefantrine when administered to treat falciparum malaria in Kemise, Northeast Ethiopia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research